This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing t ...

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

When it was discovered over a decade ago, RNAi seemed poised to revolutionize medicine. By working to silence defective genes, it has the potential to treat innumerable diseases. Has it delivered? In ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya Therapeutics focused on RNAi based therapeutics for cardiovascular diseases. The agreement covers up ...

What does Mello’s prize-winning discovery do? RNAi has garnered more than its fair share of attention lately. Being the subject of a Nobel Prize will do that. But it has also left many in the area ...

On Friday, the Food and Drug Administration approved the first-ever drug to rely on a Nobel-prize-winning technique that mutes disease-causing genes — a watershed moment for that field of research, ...

RNAi is a powerful tool to used to define cellular mechanisms, and analyze the gene functions of various organisms in laboratories worldwide. Credit: petarg/ Shutterstock.com Fragments of RNA ...

Farmers looking to gain the upper hand over corn rootworm (CRW) pests have new tools to deploy in the field, thanks to Ribonucleic acid interference (RNAi) technology. RNAi works in CRW as it feeds on ...